Parenterals: Sterilization, Packaging, Labeling, Insulin SVPs, and LVPs

A comprehensive vocabulary flashcard set covering Parenterals: Sterilization methods, endotoxin control, packaging, labeling, insulin SVPs, and LVPs.

Sterility

The complete absence of viable microorganisms in a product.

Endotoxin / Pyrogen Control

The absence or control of fever-producing contaminants in a parenteral formulation.

Sterility vs. Endotoxin-Free Relationship

The principle that a sterile product is not necessarily endotoxin-free, as killing bacteria does not automatically destroy endotoxins.

Bacterial Endotoxin

Lipopolysaccharide (LPS) originating from the outer membrane of Gram-negative bacteria.

Steam Sterilization

The preferred sterilization method using saturated steam under pressure for products and containers that tolerate heat and moisture.

Autoclave

A pressure vessel operating similarly to a pressure cooker used to achieve high steam temperatures above atmospheric pressure.

Atmospheric Steam Temperature Limitation

Water vapor at atmospheric pressure reaches only $100^\text{o}\text{C}$, which is not hot enough to kill all bacteria.

Steam Sterilization Parameter ($121.5^\text{o}\text{C}$)

Exposure to saturated steam at $15\text{ pounds}$ of pressure at a temperature of $121.5^\text{o}\text{C}$ for $20\text{ minutes}$.

Steam Sterilization Parameter ($126.5^\text{o}\text{C}$)

Exposure to saturated steam at $20\text{ pounds}$ of pressure at a temperature of $126.5^\text{o}\text{C}$ for $15\text{ minutes}$.

Steam Sterilization Lethality Determinants

The combined effect of temperature, time, saturated steam, and adequate steam penetration.

Terminal Steam Sterilization Decision Rule

The preferred method when the drug, formulation, moisture, and container/closure system are all heat- and moisture-stable.

Dry-Heat Sterilization

A form of sterilization using heat only without moisture or pressure, operating by the oxidation of cellular constituents.

Dry-Heat Sterilization Operating Parameters

Process requiring higher temperatures of $160\text{--}170^\text{o}\text{C}$ for an exposure period of at least $2\text{ hours}$.

Dry-Heat Sterilization Materials

Substrates including glassware, metals, oils, powders, and materials incompatible with moisture.

Depyrogenation of Glassware

The removal or inactivation of endotoxins from glass containers and components using validated high-temperature dry heat.

Sterile Filtration

Physical removal of microorganisms from heat-labile solutions using a sterilizing-grade filter followed by aseptic filling.

Sterilizing-Grade Filter Pore Size

A membrane filter with a validated pore size of $0.2\text{ }\text{or}\text{ }0.22\text{ }\text{microns}$ to physically retain bacteria.

Clarification Filter Pore Size

A filter pore size of $0.45\text{ }\text{microns}$ used for clarification and particulate reduction rather than sterilizing filtration.

Suspension Filtration Limitation

Sterile filtration cannot be used for suspensions because filter pores remove suspended active drug particles along with microbes.

Filtration Practical Considerations

Critical operational factors including product heat-lability, solution viscosity/filterability, and filter integrity validation.

Gas Sterilization

A low-temperature sterilization process using ethylene oxide (EtO) gas primarily for heat- and moisture-sensitive medical devices.

Ethylene Oxide Mechanism of Action

Microbial destruction achieved through the chemical alkylation of cellular proteins, DNA, and RNA.

Ethylene Oxide Major Limitation

Leaves toxic residual EtO on products, requiring a dedicated aeration process prior to safe product distribution.

Ethylene Oxide Applications

Sterilization of surgical instruments, needles, syringes, and disposable plastics.

Ethylene Oxide Packaging Requirement

Packaging must allow EtO gas penetration during processing and subsequent aeration of toxic residuals.

Radiation Penetration Diagram

A diagram illustrating the relative penetration depth of radiation types (Alpha, Beta, Gamma, X-ray, Neutron) through Paper, Wood, and Lead.

Ionizing Radiation Sterilization

A cold sterilization process using high-energy, penetrating gamma radiation or electron beams (E-beam).

Ionizing Radiation Mechanism of Action

Microbial inactivation caused by direct cellular DNA damage.

Ionizing Radiation Advantages

Functions as a cold process without heat and can penetrate densely packed finished products.

Ionizing Radiation Applications

Sterilization of disposable devices, syringes, ointments, raw ingredients, and heat-sensitive drugs.

Method Selection: Aqueous + Heat-Stable

Terminal steam sterilization.

Method Selection: Oil / Powder / Glass

Dry-heat sterilization.

Method Selection: Heat-Labile Solution

Sterile filtration followed by aseptic filling.

Method Selection: Heat-Sensitive Device

Ethylene oxide (EtO) gas sterilization.

Method Selection: Packaged Disposable / Device

Ionizing radiation (gamma / E-beam).

Sterilization Process Validation

Documented evidence confirming that a sterilization process consistently achieves microbial destruction.

Physical Sterilization Indicators

Monitoring parameters during sterilization, such as temperature, pressure, and exposure time measurements.

Chemical Sterilization Indicators

Indicators such as autoclave tape or colorimetric indicators that undergo visual changes upon exposure to sterilization conditions.

Biological Sterilization Indicators

Preparations containing standardized resistant bacterial spores used to directly demonstrate microbial kill.

Autoclave Tape & Colorimetric Indicators

Chemical monitoring tools demonstrating physical or color changes before and after autoclave processing to verify exposure.

First Principle of Endotoxin Control

Preventing endotoxin introduction into the product through Water for Injection (WFI), raw components, equipment, and bioburden control.

Bacterial Endotoxins Test (BET)

A compendial analytical test utilizing LAL assays or recombinant reagents to measure bacterial endotoxins.

Limulus Amebocyte Lysate (LAL)

A traditional gel-clot or photometric reagent derived from horseshoe crab blood cells used to detect bacterial endotoxins.

Recombinant Factor C (rFC)

A non-animal recombinant reagent and cascade approach recognized under USP

FDA March 2026 Endotoxin Guidance

Regulatory guidance specifically accommodating the use of recombinant reagents for bacterial endotoxin testing.

Sterilization (Summary Concept)

Purpose is to destroy or remove viable microorganisms using steam, dry heat, or filtration.

Aseptic Processing (Summary Concept)

Purpose is to prevent recontamination after sterile components are prepared, such as sterile filtration paired with aseptic filling.

Depyrogenation (Summary Concept)

Purpose is to remove or inactivate endotoxins using validated high-temperature dry heat.

Endotoxin Testing (Summary Concept)

Purpose is to demonstrate that endotoxin levels are below the designated product-specific limit using the Bacterial Endotoxins Test.

Container-Closure Compatibility

Requirements ensuring packaging protects sterility, avoids interaction with the formulation, and permits visual inspection.

Single-Dose Container Rule

Packaging intended for a single patient/procedure that cannot be re-sealed once opened; unused portions must be discarded.

Multiple-Dose Container Rule

Packaging permitting repeated dose withdrawals using aseptic technique while maintaining product purity.

Ampule

A single-dose glass container sealed by fusion under aseptic conditions, opened by snapping off the glass top.

Filter Needle for Ampules

A specialized needle required to withdraw solution from a snapped glass ampule to trap potential glass fragments.

Single-Dose Vial

A single-use glass or plastic container holding liquid or powder for reconstitution.

Disposable Pre-Filled Syringe

A single-use, pre-measured parenteral delivery system intended for direct administration to a single patient.

Multiple-Dose Vial Volume Limit

Vials equipped with rubber closures designated for multiple dosing are limited to a maximum volume of $≤ 30\text{ mL}$.

Self-Sealing Rubber Closure

An elastomeric closure that reseals automatically upon removal of a needle after penetration.

Antimicrobial Preservatives in Multiple-Dose Containers

Mandatory additives (unless exempt) included in multiple-dose parenterals to inhibit microbial growth from repeated entries.

Parenteral Label Requirement: Preparation Name

Mandated prominent statement of the official title or drug name on the primary container label.

Parenteral Label Requirement: Strength

Mandated statement displaying percentage strength and amount per volume for liquids, or active mass and diluent volume for powders.

Parenteral Label Requirement: Route of Administration

Mandated explicit labeling stating the intended injection route (e.g., I.M., I.V., S.C.).

Parenteral Label Requirement: Visual Inspection Window

Label arrangement that leaves a portion of the glass container clear to allow visual examination of solution contents.

Reconstitution Label Information

Directions on powder vial labels specifying that the drug must be reconstituted, identifying the required diluent, and stating the final concentration.

Poppers for Reconstitution

Integrated drug-and-diluent container systems enabling rapid, sterile mixing of dry powder vials with diluent IV bags prior to administration.

Small Volume Parenteral (SVP)

An injectable product packaged in a container holding a volume of $≤ 100\text{ mL}$.

Large Volume Parenteral (LVP)

A single-dose, sterile, endotoxin-controlled aqueous intravenous solution packaged in a container holding $> 100\text{ mL}$.

Insulin Structure & Function

A hormone of $∼ 5.8\text{ kDa}$ containing $51\text{ amino acids}$ secreted by the pancreas to regulate glucose metabolism.

Insulin Route Selection

Administered subcutaneously because oral administration results in enzymatic protein degradation within the gastrointestinal tract.

Recombinant Human Insulin

Modern human insulin and insulin analogs synthesized using recombinant DNA technology.

Four Variables of Insulin Performance

Physical form, molecular analog design, excipients, and route/device selection.

Pharmacokinetic Parameters of Insulin Formulations

Performance metrics evaluated by onset of action, time to peak action, and duration of action.

Regular Insulin (Insulin Injection, USP)

A clear aqueous solution of zinc-insulin crystals used for short-acting subcutaneous control or emergency rapid intravenous titration.

Phenol / Cresol in Regular Insulin

Antimicrobial preservative excipients added to regular insulin solutions.

Insulin Storage Precautions

Must be refrigerated, never frozen (freezing damages the protein), and not injected cold to prevent localized lipodystrophy.

Lipodystrophy

Adipose tissue breakdown or altered structure caused by injecting cold insulin solutions into subcutaneous sites.

NPH Insulin (Isophane Insulin Suspension)

A cloudy, intermediate-acting subcutaneous suspension of zinc-insulin crystals complexed with protamine.

Isophane / NPH Absorption Mechanism

Protamine-insulin crystals dissolve slowly following subcutaneous injection, extending action to $12\text{--}16\text{ hours}$.

NPH Administration Restriction

Must be administered subcutaneously only; it must never be administered intravenously because it is a particulate suspension.

Regular and NPH Insulin Mixtures

Pre-mixed subcutaneous combinations (e.g., 70/30 or 50/50 NPH/Regular) providing rapid onset from Regular and extended duration from NPH.

Insulin Self-Association

The tendency of regular insulin molecules in solution to self-associate into hexamers, which must dissociate into monomers before SC absorption occurs.

Rapid-Acting Insulin Analogs

Recombinant analogs (lispro, aspart, glulisine) with altered amino acid sequences that decrease hexamer formation for fast absorption.

Insulin Lispro (Humalog®)

A rapid-acting recombinant analog administered prior to meals for prandial coverage, featuring a $2\text{--}4\text{ hour}$ duration.

Insulin Glargine (Lantus®)

A basal insulin formulated as an acidic solution ($\text{pH } 4$) that forms microprecipitates at neutral subcutaneous pH, releasing insulin over $∼ 20\text{ hours}$.

Insulin Degludec (Tresiba®)

An ultra-long-acting basal insulin that forms soluble multihexamer chains in subcutaneous tissue, yielding a flat profile lasting $42\text{ hours}$.

Ultra-Rapid Insulin Aspart (Fiasp®)

An ultra-rapid prandial formulation of insulin aspart containing niacinamide to accelerate early subcutaneous absorption.

Ultra-Rapid Insulin Lispro (Lyumjev®)

An ultra-rapid formulation containing insulin lispro-aabc with citrate and treprostinil excipients to increase local blood flow and speed absorption.

Excipient Engineering in Insulin Formulations

Using specific excipients to modify subcutaneous absorption rates without altering the underlying cellular glucose-lowering mechanism.

Afrezza®

A non-parenteral, rapid-acting dry powder formulation of human insulin administered by oral inhalation.

Continuous Subcutaneous Insulin Infusion (CSII)

An administration system using a programmable pump to deliver rapid-acting insulin subcutaneously for basal rates and mealtime boluses.

CSII Infusion Site Rotation

Clinical practice requiring replacement of subcutaneous infusion sets and site rotation every $3\text{ days}$.

Continuous Glucose Monitor (CGM)

A wearable sensor device that measures interstitial glucose levels continuously in real time.

Automated Insulin Delivery (AID) / Hybrid Closed-Loop System

A system linking a continuous glucose monitor (CGM), control algorithm, and insulin pump to automatically manage insulin delivery.

LVP Preservative Exemption

Large Volume Parenterals do not contain antimicrobial preservatives because administering high fluid volumes would cause preservative toxicity.

Primary Uses of LVPs

Intravenous administration for fluid/electrolyte replenishment, parenteral nutrition, and as vehicles for continuous drug infusions.

LVP Single-Dose Rule

LVPs are packaged strictly in single-dose containers (bags/bottles) to avoid microbial contamination in unpreserved solutions.

Look-Alike Medication Hazard in Parenterals

A safety risk where products with vastly different potencies (e.g., Heparin $10\text{ U/mL}$ vs. $10,000\text{ U/mL}$) look visually similar.

IV Line Adsorption

Loss of active drug potency caused by drug molecules binding to the inner surface of glass containers, plastic bags, or IV tubing.

Chemotherapeutic Parenteral Risk

Parenteral administration of hazardous drugs requiring special containment, protective handling, and disposal protocols.

High-Risk Factors of IV Admixtures

Hazards including dose/calculation errors, physical/chemical incompatibilities, precipitation, line contamination, and rate errors.